VXRT News and Press, Vaxart Inc. From 09/04/19

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C....

Vaxart (NASDAQ: VXRT ): Q2 GAAP EPS of -$0.39 beats by $0.11 . More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- Phase 1b Bivalent Norovirus Study Fully Enrolled - - Research Collaboration with Janssen for Universal Flu Vaccine Underway - Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, tod...

Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a ...

Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory S...

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer revi...

Vaxart (NASDAQ: VXRT ): Q1 GAAP EPS of -$0.18. More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- $13 million raised in 1H19 - - Norovirus bivalent vaccine Phase 1b clinical study underway with results expected in 2H19 - Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today a...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial. “W...

100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scie...